Antiviral activity of gemcitabine against human rhinovirus in vitro and in vivo

Song, Jae-Hyoung; Kim, Seong-Ryeol; Heo, Eunyoung; Lee, Jae-Young; Kim, Dongeun; Cho, Sungchan; Chang, Shau‐Jin; Yoon, Byung–Il; Seong, Jeong-Min; Ko, Hyun‐Jeong

doi:10.1016/j.antiviral.2017.07.003

Cited by 25 publications

(18 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, experimental data on the antiviral activity of gemcitabine have been widely reported (Shin et al, 2018;Ianevski et al, 2019). The broad range of viruses against which gemcitabine has shown activity includes HIV-1 (Rawson et al, 2013;Clouser et al, 2010Clouser et al, , 2012, murine leukaemia virus (MuLV) (Clouser et al, 2012), HIV-2 (Beach et al, 2014), ZIKV (Kuivanen et al, 2017), enteroviruses such as poliovirus (Kang et al, 2015;Zhang et al, 2017), rhinoviruses (Song et al, 2017), HCV (Beran et al, 2012), coronaviruses (Dyall et al, 2014), Sindbis virus (SINV), HSV-1 and FLUAV (Denisova et al, 2012). The synergistic effect of gemcitabine combined with low doses of other nucleoside analogues was also reported.…”

Section: Nucleoside Antimetabolites -Approved Antineoplastic Drugs Wimentioning

confidence: 99%

“…Another possibility is that the viral ribonucleotide reductase is inhibited, resulting in an increased mutation rate and loss of viral proliferation capability (Kang et al, 2015). It was postulated that the inhibition of RNA replication might be related to the limited amount of nucleoside available (Song et al, 2017). As a cytidine analogue, gemcitabine was reported to inhibit the salvage pathway of the pyrimidine biosynthesis.…”

Section: Nucleoside Antimetabolites -Approved Antineoplastic Drugs Wimentioning

confidence: 99%

“…Myelodysplastic syndrome (2004) AdV (Alexeeva et al (2001); (Alexeeva et al, 2015) HMPV (Bösl et al, 2019) HIV-1 (Dapp et al, 2009;Rawson et al, 2016a) HIV-1 -synergy in combination with resveratrol (Rawson et al, 2016b) HIV-2 (Beach et al, 2014) RVFV ( (Clouser et al, 2012) HIV-1 -synergy in combination with decitabine (Clouser et al, 2010) MuLV (Clouser et al, 2012) HIV-2 (Beach et al, 2014) ZIKV (Kuivanen et al, 2017) Enteroviruses including poliovirus (Kang et al, 2015;Zhang et al, 2017) Enteroviruses -synergy with ribavirin (Kang et al, 2015) Rhinoviruses (Song et al, 2017) HCV (Beran et al, 2012) Coronaviruses (Dyall et al, 2014) SINV, HSV-1, FLUAV (Denisova et al, 2012) Gram-positive bacteria (Jordheim et al, 2012;Sandrini et al, 2007;…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Selected nucleos(t)ide-based prescribed drugs and their multi-target activity

Pastuch-Gawołek

Gillner

Król

et al. 2019

European Journal of Pharmacology

View full text Add to dashboard Cite

A B S T R A C T Nucleos(t)ide analogues play pivotal roles as antiviral, cytotoxic or immunosuppressive agents. Here, we review recent reports of nucleoside analogues that exhibit broad-spectrum activity towards multiple life-threatening RNA and DNA viruses. We also present a discussion about nucleoside antimetabolites-approved antineoplastic agents-that have recently been shown to have antiviral and/or antibacterial activity. The approved drugs and drug combinations, as well as recently identified candidates for investigation and/or experimentation, are discussed. Several examples of repurposed drugs that have already been approved for use are presented. This strategy can be crucial for the first-line treatment of acute infections or coinfections and for the management of drug-resistant strains.T against viral infections of great medical importance (e.g., herpes simplex virus (HSV), varicella zoster virus (VZV), human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV)) and/or that are known antineoplastic agents used to treat cancer. Approved nucleos(t)ide-based drugs with multi-target activity and compounds being tested in clinical trials or evaluated in preclinical assays are listed in Table 1. In this paper, the term "approval date" means the date on which the drug was approved by the US Food and Drug Administration (FDA) unless otherwise stated. G. Pastuch-Gawołek, et al. Multi-target nucleos(t)ide-based drugs in the treatment and prophylaxis of HIV, HBV and HCV infections

show abstract

Section: Nucleoside Antimetabolites -Approved Antineoplastic Drugs Wimentioning

confidence: 99%

Section: Nucleoside Antimetabolites -Approved Antineoplastic Drugs Wimentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Selected nucleos(t)ide-based prescribed drugs and their multi-target activity

Pastuch-Gawołek

Gillner

Król

et al. 2019

European Journal of Pharmacology

View full text Add to dashboard Cite

show abstract

“…168 Treatment with the cancer therapeutic gemcitabine (20,20-difluorodeoxycytidine) reduced RV load, inflammatory cytokine levels (TNFα, IL-1β), and reduced lung lymphocyte numbers. 169 Treatment with corticosteroid therapy (fluticasone proprionate) suppressed IFN responses to RV and reduced airway inflammation, leading to increased mucus production and reduced antimicrobial responses. 170 Effects on viral load, mucin production, and antibacterial response could be reversed by administration of recombinant IFNβ.…”

Section: Preclinical Testing In Mouse Models Of Rhinovirus Infectionmentioning

confidence: 99%

In vivo experimental models of infection and disease

Girkin

Maltby

Singanayagam

et al. 2019

Rhinovirus Infections

View full text Add to dashboard Cite

“…Strategies for the treatment of patients with EV‐A71 infection include using antipyretics, oral vitamin, pain‐relieving drugs, oral or intravenous fluids to prevent complications . So far, there are no effective antivirals against EV‐A71 in clinical practice, although numerous studies have shown that some drugs are effective in vitro or in vivo . Novel effective inhibitors of EV‐A71 need to be screened out from a large compound library by a high‐throughput screening (HTS) system.…”

Section: Introductionmentioning

confidence: 99%

An antiviral drug screening system for enterovirus 71 based on an improved plaque assay: A potential high‐throughput method

Yin

et al. 2019

Journal of Medical Virology

View full text Add to dashboard Cite

Plaque assay plays an irreplaceable role in a variety of virological studies, including determining titers of viruses. Our previous study showed that a simple and highly repeatable plaque assay could be used for enterovirus 71 (EV-A71). Now, we show that using a subclone of a clinical EV-A71 isolate and a rhabdomyosarcoma cell line (RD), a plaque assay based on an EV-A71/RD model could exhibit the most rapid formation of plaques (<2 days), with much higher repeatability and consistency.Inspired by a plaque inhibitory test for testing ribavirin and interferon, as well as a plaque reduction neutralization test, this modified method has been used to establish a convenient system by using 96-well plates for screening anti-EV-A71 drugs from a 130-compound library containing multiple types of inhibitors. Nine candidate effective compounds for EV-A71 have been screened out, and among them, nobiletin (flavonoid) was found to be a novel effective compound at the concentration of 10 μM.Our findings imply that this improved method based on an EV-A71/RD model proved to be a potential high-throughput method in screening novel antiviral drugs for EV-A71. Undoubtedly, this method can also be applied to other viruses that can produce an obvious cytopathic effect. K E Y W O R D Santiviral drug screening, enterovirus 71, plaque assay, plaque inhibitory test antiviral drug screening system for enterovirus 71 based on an improved plaque assay: A potential high-throughput method.

show abstract

Antiviral activity of gemcitabine against human rhinovirus in vitro and in vivo

Cited by 25 publications

References 32 publications

Selected nucleos(t)ide-based prescribed drugs and their multi-target activity

Selected nucleos(t)ide-based prescribed drugs and their multi-target activity

In vivo experimental models of infection and disease

An antiviral drug screening system for enterovirus 71 based on an improved plaque assay: A potential high‐throughput method

Contact Info

Product

Resources

About